Plenty in Myeloma Pipeline; What Regulatory Path Ahead?
Multiple myeloma patients have gone from no options to three approved drugs in the past decade. And that fact is presumably part of what prompted the FDA's decision to refuse to give a priority review to Onyx Pharmaceuticals Inc.'s carfilzomib.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter